2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. mGluR
  5. mGluR Isoform
  6. mGluR Antagonist

mGluR Antagonist

mGluR Antagonists (34):

Cat. No. Product Name Effect Purity
  • HY-100406
    (S)-MCPG
    		Antagonist 99.02%
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371). (S)-MCPG can be used for the study of the function of mGluRs in spatial learning.
  • HY-100371
    (RS)-MCPG
    		Antagonist 99.05%
    (RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons.
  • HY-101333
    CPPG
    		Antagonist ≥99.0%
    CPPG ((RS)-CPPG) is a potent group II/III mGlu receptors antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50=2.2 nM) over group II (IC50=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors.
  • HY-101226
    MSOP
    		Antagonist ≥98.0%
    MSOP is a selective group III metabotropic glutamate receptor antagonist with apparent KD of 51 μM for the L-AP4-sensitive presynaptic mGluR.
  • HY-102094
    (E/Z)-SIB-1893
    		Antagonist 99.79%
    (E/Z)-SIB-1893 is a racemic compound of (E)-SIB-1893 and (Z)-SIB-1893 isomers. (E)-SIB-1893 is a selective non-competitive metabotropic glutamate subtype 5 receptor (mGluR5) antagonist.
  • HY-103566
    LY456236
    		Antagonist 99.81%
    LY456236 is a selective, non-competitive and orally active mGlu1 receptor antagonist that inhibits phosphoinositide hydrolysis with an IC50 of 0.145 μM. LY456236 also inhibits EGFR with an IC50 of 0.91 μM.
  • HY-100372
    E4CPG
    		Antagonist ≥98.0%
    E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation.
  • HY-100409
    PHCCC
    		Antagonist 99.92%
    PHCCC is a Group I mGluR antagonist with an IC50 of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect.
  • HY-155352
    mGluR5 antagonist-1
    		Antagonist 98.80%
    mGluR5 antagonist-1 (compound 10) is a high-affinity mGluR5 antagonist, with an IC50 value of 11.5 nM. mGluR5 antagonist-1 has anti-depressant effect.
  • HY-119097
    LY456066
    		Antagonist ≥99%
    LY456066 is a selective non-competitive metabotropic glutamate receptors (mGluR1) antagonist with an IC50 value of 52.0 nM. LY456066 is effective in rodent models of anxiolysis and nociception. LY456066 reduces hyperalgesia and the amount of licking and flinching following formalin injection, which is promising for research of analgesics for chronic pain.
  • HY-103567
    Desmethyl-YM-298198 hydrochloride
    		Antagonist
    Desmethyl-YM-298198 hydrochloride is a high-affinity, selective, and noncompetitive mGluR1 antagonist (IC50: 16 nM). Desmethyl-YM-298198 hydrochloride has analgesic effect in Streptozotocin (HY-13753)-induced hyperalgesic mice.
  • HY-103564
    ACDPP
    		Antagonist
    ACDPP is a specific mGluR5 antagonist. ACDPP partially bolcks the increase of fragile X mental retardation protein (FMRP) caused by DHPG (HY-12598A) (group I mGluR Agonist).
  • HY-103571
    VU0285683
    		Antagonist
    VU0285683 is a selective mGluR5 positive allosteric modulator (PAM). VU0285683 has anxiolytic-like activity in rodent models for anxiety.
  • HY-136587R
    Oxomemazine (Standard)
    		Antagonist
    Oxomemazine (Standard) is the analytical standard of Oxomemazine. This product is intended for research and analytical applications. Oxomemazine is a phenothiazine-based histamine H1-receptor blocker with pronounced antimuscarinic properties. Oxomemazine is a selective antagonist for muscarinic M1 receptor, displays about 20-fold difference in the affinity for high (Ki = 84 nM, M1 receptor) and low (Ki = 1.65 μM, M2 receptor) affinity sites. Oxomemazine an antihistamine and anticholinergic agent used for the study of cough treatment.
  • HY-103570
    MCPG sodium
    		Antagonist
    MCPG is a carboxylic phenyl glycine. MCPG can block metabotropic glutamate receptor (mGluR)(HY-15129) and has antagonistic activity of mGluR subtype. MCPG can be used to study the induction and maintenance of long-term potentiation (LTP) .
  • HY-103560
    (S)-HexylHIBO
    		Antagonist
    (S)-HexylHIBO is the S-enantiomer of HexylHIBO. HexylHIBO is a group I mGluR antagonist. HexylHIBO elevates the hypothalamus-pituitary-adrenal axis response to restraint in rats. HexylHIBO is promising for research of central nervous system-related diseases.
  • HY-103557
    Ro 64-5229
    		Antagonist
    Ro 64-5229 is a selective, non-competitive mGlu2 antagonist. RO 64-5229 reduces the presynaptic inhibitory effect of Neuroligin 1.
  • HY-101247
    MTPG
    		Antagonist
    MTPG is a potent mGluR2 and mGluR3 antagonist. MTPG can block the induction of brain ischemic tolerance induced by cerebral ischemic preconditioning. MTPG also significantly attenuates the inhibitory effect of L-CCG-1 on the KCl-evoked dopamine release.
  • HY-110146
    XAP044
    		Antagonist
    XAP044 is a potent and selective antagonist of mGlu7. The metabotropic glutamate receptor subtype 7 (mGlu7) is an important presynaptic regulator of neurotransmission in the mammalian CNS. XAP044 demonstrates good brain exposure and wide spectrum anti-stress and antidepressant- and anxiolytic-like efficacy in rodent behavioral paradigms.
  • HY-135464
    (±)-LY367385
    		Antagonist ≥98.0%
    (±)-LY367385 is the racemate of LY367385. LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a.